Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19., Blood, 116, 4099, 10.1182/blood-2010-04-281931 Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia., Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842 Brentjens, 2011, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias., Blood, 118, 4817, 10.1182/blood-2011-04-348540 Dudley, 2008, Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens., J Clin Oncol, 26, 5233, 10.1200/JCO.2008.16.5449 Brentjens, 2003, Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15., Nat Med, 9, 279, 10.1038/nm827 Brentjens, 2007, Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts., Clin Cancer Res, 13, 5426, 10.1158/1078-0432.CCR-07-0674 Kohn, 2011, CARs on track in the clinic., Mol Ther, 19, 432, 10.1038/mt.2011.1 Lamers, 2011, Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells., Blood, 117, 72, 10.1182/blood-2010-07-294520 Kershaw, 2006, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer., Clin Cancer Res, 12, 6106, 10.1158/1078-0432.CCR-06-1183 Park, 2007, Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma., Mol Ther, 15, 825, 10.1038/sj.mt.6300104 Till, 2008, Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells., Blood, 112, 2261, 10.1182/blood-2007-12-128843 Savoldo, 2011, CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients., J Clin Invest, 121, 1822, 10.1172/JCI46110 Zhou, 1994, Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development., Mol Cell Biol, 14, 3884, 10.1128/MCB.14.6.3884 Ferrone, 2006, Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains., Clin Cancer Res, 12, 5511, 10.1158/1078-0432.CCR-06-0979 Lee, 2009, Retroviral transduction of murine primary T lymphocytes., Methods Mol Biol, 506, 83, 10.1007/978-1-59745-409-4_7 Gong, 1999, Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen., Neoplasia, 1, 123, 10.1038/sj.neo.7900018 Lee, 2011, In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy., Cancer Res, 71, 2871, 10.1158/0008-5472.CAN-10-0552 Uchida, 2004, The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy., J Exp Med, 199, 1659, 10.1084/jem.20040119 James, 2009, Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice., Blood, 114, 5454, 10.1182/blood-2009-08-232967 Lisiero, 2011, Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model., J Immunol, 186, 5068, 10.4049/jimmunol.1003317 Kochenderfer, 2010, Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells., Blood, 116, 3875, 10.1182/blood-2010-01-265041 Louis, 2011, Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma., Blood, 118, 6050, 10.1182/blood-2011-05-354449 Pule, 2008, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma., Nat Med, 14, 1264, 10.1038/nm.1882 Gattinoni, 2005, Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells., J Exp Med, 202, 907, 10.1084/jem.20050732 Bracci, 2007, Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration., Clin Cancer Res, 13, 644, 10.1158/1078-0432.CCR-06-1209 Ghiringhelli, 2004, CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative., Eur J Immunol, 34, 336, 10.1002/eji.200324181 Paulos, 2007, Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling., J Clin Invest, 117, 2197, 10.1172/JCI32205 Trinchieri, 2003, Interleukin-12 and the regulation of innate resistance and adaptive immunity., Nat Rev Immunol, 3, 133, 10.1038/nri1001 Curtsinger, 2003, Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function., J Exp Med, 197, 1141, 10.1084/jem.20021910 Curtsinger, 2005, Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytolysis., J Immunol, 175, 4392, 10.4049/jimmunol.175.7.4392 Kilinc, 2006, Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors., J Immunol, 177, 6962, 10.4049/jimmunol.177.10.6962 Cao, 2009, Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance., Cancer Res, 69, 8700, 10.1158/0008-5472.CAN-09-1145 Cavallo, 1999, Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12., Cancer Res, 59, 414 Zhao, 2011, Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens., Mol Ther, 19, 805, 10.1038/mt.2010.295 Kerkar, 2010, Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts., Cancer Res, 70, 6725, 10.1158/0008-5472.CAN-10-0735 Atkins, 1997, Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies., Clin Cancer Res, 3, 409 Gollob, 2001, Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12., J Immunother, 24, 91, 10.1097/00002371-200101000-00011 Wadler, 2004, A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96., Gynecol Oncol, 92, 957, 10.1016/j.ygyno.2003.12.022 Robertson, 1999, Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer., Clin Cancer Res, 5, 9 Leonard, 1997, Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production., Blood, 90, 2541 van Herpen, 2004, Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes., Clin Cancer Res, 10, 2626, 10.1158/1078-0432.CCR-03-0304 Kerkar, 2011, IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors., J Clin Invest, 121, 4746, 10.1172/JCI58814 Chmielewski, 2011, IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression., Cancer Res, 71, 5697, 10.1158/0008-5472.CAN-11-0103